

## *List of figures*

<b>Fig. No.</b>	<b>Title</b>	<b>Page No.</b>
<b>2.01</b>	Orally active antihypertensive agents	<b>31</b>
<b>2.02</b>	Biologically active dihydropyrimidine molecules	<b>32</b>
<b>2.03</b>	Marine natural alkaloids with DHPM core unit	<b>32</b>
<b>2.04</b>	Biological active dihydropyrimidines	<b>33</b>
<b>2.05</b>	Three major possible mechanisms of the Biginelli reaction	<b>44</b>
<b>2.06</b>	Hepatitis B Virus (HBV) capsid inhibitors	<b>65</b>
<b>3.01</b>	1,4-DHP drugs for cardiovascular diseases	<b>91</b>
<b>3.02</b>	Biologically active pyrido[2,3-d]pyrimidine frameworks	<b>98</b>
<b>3.03</b>	Biological active compounds with quinoline ring system	<b>104</b>
<b>3.04</b>	Skraup reaction (A); Doebner reaction (B); Doebner–Von Miller reaction (C); Conrad–Limpach reaction (D); and Povarov reaction (E)	<b>105</b>
<b>3.05</b>	Quinoline synthesis methods: Friedländer reaction (F); and Pfitzinger reaction (G).	<b>106</b>
<b>4.1</b>	Pyrimidine-5-carboxylates and carboxamides with known biological activity	<b>145</b>
<b>4.2</b>	Biological active imidazo[1,2- <i>a</i> ]pyrimidines	<b>159</b>
<b>5.1</b>	Pyrimidine-5-carboxylates and carboxamides with known biological activity	<b>184</b>
<b>5.2</b>	Biological active dihydropyrimidines	<b>186</b>
<b>5.3</b>	Novel cell-permeable molecule	<b>186</b>

<b>5.4</b>	Biological active alkaloids	<b>186</b>
<b>5.5</b>	Equipotent drug containing pyrimidine ring	<b>189</b>
<b>5.6</b>	Inhibitors of UT-B and PTP1B and the screening hit PO1	<b>193</b>